Suppr超能文献

≥7厘米肾肿瘤患者的淋巴结清扫分析

Analysis of lymph node dissection in patients with ≥7-cm renal tumors.

作者信息

Feuerstein Michael A, Kent Matthew, Bazzi Wassim M, Bernstein Melanie, Russo Paul

机构信息

Urology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA,

出版信息

World J Urol. 2014 Dec;32(6):1531-6. doi: 10.1007/s00345-013-1233-x. Epub 2014 Jan 9.

Abstract

PURPOSE

To analyze the role of lymph node dissection (LND) in patients with large renal tumors.

METHODS

We performed a retrospective study of patients with renal cell carcinoma ≥7 cm in size undergoing surgery between 1990 and 2012. Primary outcome measures were recurrence-free and overall survival of patients who did and did not undergo LND. Cox proportional hazards regression models were created to account for known risk factors for recurrence and survival. Secondary outcomes were recurrence-free and overall survival by lymph node status, lymph node template and number of lymph nodes removed.

RESULTS

Of 524 patients, 164 had disease recurrence and 197 died. Median follow-up was 5 and 5.5 years for patients who did not die or have a recurrence, respectively. A total of 334 (64 %) patients underwent LND, and node-positive disease was identified in 26 (8 %). For patients who did and did not undergo LND, 5-year recurrence-free survival was 64 and 77 %, respectively. Five-year overall survival was 75 and 78 %, respectively. LND was not a predictor of recurrence or survival in multivariate analysis. Node-positive disease was associated with recurrence (p < 0.0005) and mortality (p = 0.032), although node-positive patients had a 5-year overall survival of 65 %.

CONCLUSIONS

We did not find a difference in recurrence-free or overall survival in patients with ≥7-cm tumors whether or not they underwent LND. Node-positive disease was associated with worse outcomes, suggesting that LND provides important staging information that can be important in the design of adjuvant clinical trials.

摘要

目的

分析淋巴结清扫术(LND)在大体积肾肿瘤患者中的作用。

方法

我们对1990年至2012年间接受手术的肾细胞癌大小≥7 cm的患者进行了一项回顾性研究。主要观察指标是接受和未接受LND的患者的无复发生存率和总生存率。建立Cox比例风险回归模型以考虑已知的复发和生存风险因素。次要观察指标是按淋巴结状态、淋巴结模板和切除淋巴结数量划分的无复发生存率和总生存率。

结果

524例患者中,164例出现疾病复发,197例死亡。未死亡或未复发患者的中位随访时间分别为5年和5.5年。共有334例(64%)患者接受了LND,其中26例(8%)被确诊为淋巴结阳性疾病。接受和未接受LND的患者,5年无复发生存率分别为64%和77%。5年总生存率分别为75%和78%。在多变量分析中,LND不是复发或生存的预测因素。淋巴结阳性疾病与复发(p < 0.0005)和死亡率(p = 0.032)相关,尽管淋巴结阳性患者的5年总生存率为65%。

结论

我们发现,肿瘤大小≥7 cm的患者无论是否接受LND,其无复发生存率或总生存率均无差异。淋巴结阳性疾病与较差的预后相关,这表明LND提供了重要的分期信息,在辅助性临床试验设计中可能很重要。

相似文献

1
Analysis of lymph node dissection in patients with ≥7-cm renal tumors.
World J Urol. 2014 Dec;32(6):1531-6. doi: 10.1007/s00345-013-1233-x. Epub 2014 Jan 9.
5
Lymph node dissection during radical nephrectomy: A Canadian multi-institutional analysis.
Urol Oncol. 2021 Jun;39(6):371.e17-371.e25. doi: 10.1016/j.urolonc.2021.02.025. Epub 2021 Mar 27.
9
Lymph node dissection in renal cell carcinoma.
Eur Urol. 2011 Dec;60(6):1212-20. doi: 10.1016/j.eururo.2011.09.003. Epub 2011 Sep 13.
10
Pathologic Predictors of Survival During Lymph Node Dissection for Metastatic Renal-Cell Carcinoma: Results From a Multicenter Collaboration.
Clin Genitourin Cancer. 2018 Apr;16(2):e443-e450. doi: 10.1016/j.clgc.2017.10.004. Epub 2017 Oct 17.

引用本文的文献

2
The Current Role of Lymph Node Dissection in Nonmetastatic Localized Renal Cell Carcinoma.
J Clin Med. 2023 May 29;12(11):3732. doi: 10.3390/jcm12113732.
3
Using machine learning to predict lymph node metastasis in patients with renal cell carcinoma: A population-based study.
Front Public Health. 2023 Mar 24;11:1104931. doi: 10.3389/fpubh.2023.1104931. eCollection 2023.
5
The Role of Lymph Node Dissection for Non-Metastatic Renal Cell Carcinoma: An Updated Systematic Review and Meta-Analysis.
Front Oncol. 2022 Jan 12;11:790381. doi: 10.3389/fonc.2021.790381. eCollection 2021.
7
A Novel Preoperative Nomogram for Predicting Lymph Node Invasion in Renal Cell Carcinoma Patients Without Metastasis.
Cancer Manag Res. 2019 Nov 26;11:9961-9967. doi: 10.2147/CMAR.S218254. eCollection 2019.
8
Emulating Target Clinical Trials of Radical Nephrectomy With or Without Lymph Node Dissection for Renal Cell Carcinoma.
Urology. 2020 Jun;140:98-106. doi: 10.1016/j.urology.2020.01.039. Epub 2020 Mar 4.
9
Valuation of lymph node dissection in localized high-risk renal cell cancer using X-tile software.
Int Urol Nephrol. 2020 Feb;52(2):253-262. doi: 10.1007/s11255-019-02307-x. Epub 2019 Oct 14.

本文引用的文献

1
Lymph node excision for renal cancer.
J Urol. 2013 Feb;189(2):419-21. doi: 10.1016/j.juro.2012.11.086. Epub 2012 Nov 15.
3
Staging lymphadenectomy in renal cell carcinoma must be extended: a sensitivity curve analysis.
BJU Int. 2013 Mar;111(3):412-8. doi: 10.1111/j.1464-410X.2012.11313.x. Epub 2012 Jun 15.
4
Lymph node dissection in renal cell carcinoma.
Eur Urol. 2011 Dec;60(6):1212-20. doi: 10.1016/j.eururo.2011.09.003. Epub 2011 Sep 13.
6
The role of surgery in advanced renal cell carcinoma: cytoreductive nephrectomy and metastasectomy.
Hematol Oncol Clin North Am. 2011 Aug;25(4):753-64. doi: 10.1016/j.hoc.2011.05.002.
7
Stage-specific effect of nodal metastases on survival in patients with non-metastatic renal cell carcinoma.
BJU Int. 2009 Jan;103(1):33-7. doi: 10.1111/j.1464-410X.2008.08014.x. Epub 2008 Oct 16.
8
Lymphadenectomy combined with radical nephrectomy: to do or not to do?
Eur Urol. 2009 Jan;55(1):35-7. doi: 10.1016/j.eururo.2008.09.056. Epub 2008 Oct 7.
10
Lymph node dissection during the surgical treatment of renal cancer in the modern era.
Int Braz J Urol. 2008 Mar-Apr;34(2):132-42. doi: 10.1590/s1677-55382008000200002.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验